Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28302544 | 0.87 | SCN9A (0.46) | ARRXRARXRBRXRG | |
| SCHEMBL17843509 | 0.85 | RXRA (0.55) | ARRXRARXRBRXRGPGR | |
| SCHEMBL30104699 | 0.84 | AR (0.48) | ARRXRARXRBRXRGPGR | |
| SCHEMBL23877161 | 0.83 | AR (0.53) | ARRXRARXRBRXRGPGR | |
| SCHEMBL16959881 | 0.81 | AR (0.57) | ARPGR | |
| SCHEMBL2473339 | 0.80 | NOTUM (0.57) | ARRXRARXRBRXRGPGR | |
| SCHEMBL16952198 | 0.79 | AR (0.56) | ARPGR | |
| SCHEMBL2709797 | 0.78 | AR (0.45) | ARRXRARXRBRXRG | |
| SCHEMBL2973768 | 0.78 | PARP15 (0.46) | — | |
| SCHEMBL20515447 | 0.78 | AR (0.54) | ARRXRARXRBRXRGPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| EP-1817292-B1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-08 | — | — | EP | claimed |
| EP-1791821-B1 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-05 | — | — | EP | claimed |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2010-10-21 | — | — | US | claimed |
| US-7781473-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMS) | J & J Pharmaceutical Research & Development, LLC. (US) | 2010-08-24 | — | — | US | claimed |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | claimed |
| EP-1917246-B1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | claimed |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | claimed |
| US-7531565-B2 | Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-12 | — | — | US | claimed |
| US-7465809-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-12-16 | — | — | US | claimed |
| WO-2007005887-A2 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS, COMPOSITIONS AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-01-11 | — | — | WO | claimed |
| US-20060293317-A1 | Use of non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | US | claimed |
| EP-1467982-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA (US) | 2006-11-22 | — | — | EP | claimed |
| US-20060211756-A1 | Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | claimed |
| WO-2006055184-A2 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-26 | — | — | WO | claimed |
| US-20060063819-A1 | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | US | claimed |
| WO-2006031715-A2 | NOVEL IMIDAZOLIDIN-2-ONE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | WO | claimed |
| EP-1467982-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-20 | — | — | EP | claimed |
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | claimed |
| WO-2003059899-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063819-A1 | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885RXRA 182/4885RXRB 148/4885 |
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | NR3C1, NR3C2, MC2R | AR 65/4885RXRA 680/4885RXRB 725/4885 |
| US-20060211756-A1 | Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | AR, NR5A1, NR5A2 | AR 1/4885RXRA 142/4885RXRB 130/4885 |
| US-20060293317-A1 | Use of non-steroidal progesterone receptor modulators | SHBG, PGR, NR5A1 | AR 70/4885RXRA 216/4885RXRB 229/4885 |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | AR 1/4885RXRA 96/4885RXRB 66/4885 |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | CACNA1A, BMP4, TPX2 | AR 1942/4885RXRA 921/4885RXRB 995/4885 |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885RXRA 142/4885RXRB 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.